14892-97-8
14892-97-8 結(jié)構(gòu)式
基本信息
SCR7 PYRAZINE產(chǎn)
6,7-二苯基-2-磺?；?1H-蝶啶-4-酮
2,3-二氫-6,7-二苯基-2-硫代-4(1H)-蝶啶酮
6,7-二苯基-2-硫氧基-2,3-二氫蝶呤-4(1H)-酮
6,7-diphenyL
SCR7 pyrazine
SCR7
SCR-7
SCR 7.
6,7-Diphenyl-2-thiolumazine
6,7-Diphenyl-2-sulfanylpteridin-4-ol
"6,7-diphenyl-2-sulfanylidene-1H-pteridin-4-one
2,3-Dihydro-6,7-diphenyl-2-thioxo-4(1H)-pteridinone
6,7-Diphenyl-2-thioxo-2,3-dihydropteridin-4(1H)-one
6,7-Diphenyl-2-thioxo-2,3-dihydropteridin-4(8H)-one
物理化學性質(zhì)
常見問題列表
DNA Ligase IV
CRISPR/Cas9
SCR7 pyrazine (20-100 μM; 24 hours; MCF7 cells) treatment interferes with NHEJ in cells, leading to accumulation of unrepaired double-strand breaks (DSBs).
SCR7 pyrazine treatment shows a dose-dependent decrease in cell proliferation with IC
50
values of 40 μM, 34 μM, 44 μM, 8.5 μM, 120 μM, 10 μM and 50 μM for MCF7, A549, HeLa, T47D, A2780, HT1080 and Nalm6 cells, respectively.
In MCF7 cells, SCR7 pyrazine (20, 40 μM) treatment increases phosphorylation of ATM and activates p53, decreases MDM2, BCL2, resulting in activation of proapoptotic proteins, PUMA and BAX. And the shorter fragments of MCL1, PARP1, Caspase 3, and Caspase 9 cleavage are upregulated in a dose-dependent manner.
Western Blot Analysis
| Cell Line: | MCF7 cells |
| Concentration: | 20 μM, 40 μM, 100 μM |
| Incubation Time: | 24 hours |
| Result: | Showed an increase in levels of gH2AX foci and protein. |
SCR7 pyrazine (10 mg/kg; intraperitoneal injection; six doses; BALB/c mice) treatment significantly reduces breast adenocarcinoma-induced tumor and increases lifespan.
| Animal Model: | BALB/c mice injected with breast adenocarcinoma cells |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10) |
| Result: | Significantly reduced breast adenocarcinoma-induced tumor and increased lifespan. |